Potential Role of Electrochemotherapy as Anticancer Treatment for Cutaneous and Subcutaneous Lesions

  • Zygogianni, Anna (1st Department of Radiology, Radiotherapy Unit, Aretaieion University Hospital) ;
  • Kyrgias, George (Radiotherapy Department, Larisa University Hospital, Medical School) ;
  • Scarlatos, John (Radiotherapy Department, Agios Savvas Anticancer Hospital) ;
  • Koukourakis, Michael (Radiation Oncology Clinic, Alexandroupolis University Hospital, Medical School) ;
  • Souliotis, Kyriakos (Faculty of Social Sciences, University of Peloponnese) ;
  • Kouvaris, John (1st Department of Radiology, Radiotherapy Unit, Aretaieion University Hospital) ;
  • Kelekis, Nikolaos (2nd Department of Radiology, Radiotherapy Unit, ATTIKON University Hospital, Medical School, Kapodistrian University of Athens) ;
  • Kouloulias, Vassilis (2nd Department of Radiology, Radiotherapy Unit, ATTIKON University Hospital, Medical School, Kapodistrian University of Athens)
  • 발행 : 2016.08.01


Background: The aim of this study was to investigate whether electrochemotherapy is a clinically and cost-effective treatment option against skin tumors. Materials and Methods: We performed an analysis of the current literature based on database searches in PubMed/MEDLINE and we included articles till July 2012. Terms used for the search were 'electrochemotherapy', 'skin cancer', 'recurrence', and 'cutaneous and subcutaneous tumors'. Only papers published in English were included. In addition, we performed an analysis of the cost effectiveness of the method. Results: The combination of physics and chemistry is the foundation for electrochemotherapy and its efficacy, independent of the tumor histology. Clinical data showed that ECT is well tolerated and can be used in difficult cases without other available treatment options. The analysis also showed that the treatment is feasible and cost-effective. Conclusions: Electrochemotherapy is a clinically efficient safe and cost-effective treatment and clinicians should not hesitate to use it as alternative therapeutic modality or as palliative treatment.


  1. Campana LG, Mocellin S, Basso M, et al (2009). Bleomycinbased electrochemotherapy: Clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol, 16, 191-9.
  2. Campana LG, Valpione S, Falci C, et al (2012). The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Treat, 134, 1169-78.
  3. Cemazar M, Jarm T, Sersa G (2010). Cancer electrogene therapy with interleukin-12. Curr Gene Ther, 10, 300-11.
  4. Clarke M, Collins R, Darby S, et al (2005). Effects of radiotherapy and the differences in the extent of surgery for early breast cancer on local reccurence and 15 year survival: an overview of the randomized trials. Lancet, 366, 2087-106.
  5. Colombo GL, Matteo SD, Mir LM (2008).Cost-effectiveness analysis of electrochemotherapy with the Cliniporator trade mark vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag, 4, 541-548.
  6. Curatolo P, Quaglino P, Marenco F, et al (2012). Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesion: a two center prospective phase II trial. Ann Surg Oncol, 19, 192-8.
  7. Di Monta G, Caraco C, Benedetto L, et al (2014). Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma. Eur J Surg Oncol, 40, 61-6.
  8. Gargiulo M, Moio M, Monda G, et al (2010). Electrochemotherapy: actual considerations and clinical experience in head and neck cancers. Ann Surg, 251, 773.
  9. Giardino R, Fini M, Bonazzi V, et al (2006). Electrochemotherapy: a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues. Biomed Pharmacother, 60, 458-62.
  10. Jaroszeski MJ, Dang V, Pottinger C, et al (2000). . Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs, 11, 201-8.
  11. Larkin JO, Collins CG, Aarons S, et al (2007). Electrochemotherapy: Aspects of preclinical development and early clinical experience. Ann Surg, 245, 469-79.
  12. Marty M, Sersa G, Garbay JR, et al (2006). Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of the ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer, 4, 3-13.
  13. Matthiessen l, Chalmers R, Sainsbury DC, et al (2011). Management of cutaneous metastases using electrochemotherapy. Acta Oncol, 50, 621-9
  14. Matthiessen L, Johannesen H, Hendel H, et al (2012). Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial. Acta Oncol, 51, 713-21.
  15. Mevio N, Bertino G, Occhini A, et al (2012). Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori, 98, 308-13.
  16. Miklavcic D, Snoj M, Zupanic A, et al (2010). Towards treatment planning and treatment of deep seated solid tumors by electrochemotherapy. Biomed Eng Online, 9, 10.
  17. Mir LM, Orlowski S, Belehradek Jr, et al (1991). Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer, 27, 68 -72.
  18. Mir LM, Glass LF, Sersa G, et al (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer, 77, 2336-42.
  19. Mir LM (2001) Therapeutic perspectives of in vivo cell electropermeabilization. Biochemistry, 53, 1-10.
  20. Mir LM, Gehl J, Sersa G, et al (2006). Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC (Suppl), 4, 14-25.
  21. Quaglino P, Mortera C, Osella-Abate S, et al (2008). Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol, 15, 2215-22.
  22. Sersa G, Cemazar M, Miklavcic D (1995). Antitumor effectiveness of electrochemotherapy with cisdiamminedichloroplatinum( II) in mice. Cancer Res, 55, 3450-5.
  23. Sersa G, Stabuc B, Cemazar M,et al (2000). Electrochemotherapy with cisplatine: clinical experience in malignant melanoma patients. Clin Cancer Res, 6, 863-7.
  24. Skarlatos I, Kyrgias G, Mosa E, et al (2011). Electrochemotherapy in cancer patients: first clinical trial in Greece. In vivo, 25, 265-74.
  25. Solari N, Spagnolo F, Ponte E, et al (2014). Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol, 109, 270-4.